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Abstract
Background
Home blood-pressure (BP) monitoring is 
recommended in guidelines and is increasingly 
popular with patients and health professionals, 
but the accuracy of patients’ own monitors in 
real-world use is not known.
Aim
To assess the accuracy of home BP monitors 
used by people with hypertension, and to 
investigate factors affecting accuracy.
Design and setting
Cross-sectional, observational study in urban 
and suburban settings in central England.
Method
Patients (n = 6891) on the hypertension register 
at seven practices in the West Midlands, England, 
were surveyed to ascertain whether they owned a 
BP monitor and wanted it tested. Monitor accuracy 
was compared with a calibrated reference device 
at 50 mmHg intervals between 0–280/300 mmHg 
(static pressure test); a difference from the 
reference monitor of +/–3 mmHg at any interval 
was considered a failure. Cuff performance 
was also assessed. Results were analysed by 
frequency of use, length of time in service, make 
and model, monitor validation status, purchase 
price, and any previous testing.
Results
In total, 251 (76%, 95% confidence interval 
[95% CI] = 71 to 80%) of 331 tested devices 
passed all tests (monitors and cuffs), and 86% 
(CI] = 82 to 90%) passed the static pressure test; 
deficiencies were, primarily, because of monitors 
overestimating BP. A total of 40% of testable 
monitors were not validated. The pass rate on 
the static pressure test was greater in validated 
monitors (96%, 95% CI = 94 to 98%) versus 
unvalidated monitors (64%, 95% CI = 58 to 69%), 
those retailing for >£10 (90%, 95% CI = 86 to 
94%), those retailing for ≤£10 (66%, 95% CI = 51 to 
80%), those in use for ≤4 years (95%, 95% CI = 91 
to 98%), and those in use for >4 years (74%, 
95% CI = 67 to 82%). All in all, 12% of cuffs failed. 
Conclusion
Patients’ own BP monitor failure rate was similar 
to that demonstrated in studies performed in 
professional settings, although cuff failure was 
more frequent. Clinicians can be confident of 
the accuracy of patients’ own BP monitors if the 
devices are validated and ≤4 years old. 
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INTRODUCTION
Raised blood pressure (BP) is a key risk 
factor for the development of cardiovascular 
disease,1 a major cause of morbidity and 
mortality worldwide.2 An accurate BP 
monitoring device is fundamental to the 
diagnosis and management of hypertension. 
Self-monitored BP at home is a 
statistically significantly better predictor of 
future cardiovascular risk than manual office 
BP measurement,3 and self-monitoring 
as part of a self-management strategy is 
an effective way to improve BP control.4,5 
Home BP monitoring has gained popularity 
in recent years among both patients and 
healthcare professionals (HCPs), many of 
whom incorporate self-monitored readings 
in their treatment decisions;6 nevertheless, 
there is considerable variation in practice, 
and there remains scepticism among 
some HCPs about the accuracy of patients’ 
own readings, especially outside of a trial 
context.6,7
Although guidance on how to conduct 
self-monitoring of BP recommends use 
of validated upper-arm cuff devices, 
appropriate training, use of a pre-specified 
schedule (for example, number of days 
of readings, time of day), and physician 
verification of measurements,8,9 none to 
date recommends checking the accuracy 
of home BP monitors used by patients. 
Previous research has highlighted that 
monitors used in GP surgeries and 
community pharmacies have shown 
variation in accuracy.10,11 
Several clinical protocols12–15 exist for the 
validation of BP measuring devices but 
these are, generally, undertaken on brand-
new models and do not assess sustained 
accuracy thereafter. Typically, new monitors 
are assumed to be accurate for 2 years 
and then annual checks are undertaken 
in clinical practice. However, it is not clear 
whether this is appropriate as the drift 
in accuracy, over time, of an automated 
sphygmomanometer is not known, and a 
study investigating monitors in pharmacies 
suggested they decline in accuracy after 
18 months.11
Some automated BP monitors on sale to 
the public have been clinically validated; in 
such cases, a monitor or one with device 
equivalence16 will have passed at least one 
of the recognised accuracy protocols.12–14 
However, error rates in devices used for 
self-monitoring are unknown; this rate is 
a function of random error (variability) and 
systematic error (bias), and, ultimately, 
depends on the conditions under which a 
device is used. 
This study aimed to test — for the first 
time in the UK, to the authors’ knowledge 
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— the accuracy of monitors in use by the 
general public for the self-monitoring of BP. 
Secondary aims included to:
• determine which automated 
sphygmomanometers were currently 
used by patients;
• assess factors affecting accuracy, 
including those makes and models that 
performed best; and 
• evaluate the influence of regular use and 
length of time in service on accuracy.
METHOD
Patients on the hypertension register 
at seven practices in the West Midlands 
(in central England), UK, were sent 
an invitation letter together with a 
one-page questionnaire and a self-
addressed envelope. The questionnaire 
(Supplementary Information S1) asked if 
they owned a BP monitor and, if so, some 
basic questions about it and whether they 
wanted its accuracy to be assessed free of 
charge — this required them to bring the 
monitor into the practice at a prearranged 
time when they would meet a member 
of the research team. Practices were 
purposefully sampled by social deprivation 
(based on Index of Multiple Deprivation 
[IMD] 2010 scores) in order to achieve a 
diverse sample of monitors that were likely 
to range in affordability. IMD scores varied 
from 6.09 to 49.58.
Testing took place between March 
2016 and August 2017. Following visual 
inspection (that the machine switched on 
and had a readable display), the accuracy of 
each testable digital sphygmomanometer 
was evaluated by comparing it with a 
calibrated reference digital BP monitor 
tester (Omron PA350); tests were conducted 
at 50 mmHg intervals across a range of 
0–300 mmHg following a standard process, 
as recommended by each monitor 
manufacturer and the British Hypertension 
Society.12 A difference from the reference 
monitor of +/–3 mmHg at any testing 
interval was considered a failure. In addition 
to this static pressure test, monitors and 
cuffs underwent fast deflation tests (pass 
threshold: deflation from 260 mmHg to 
15 mmHg in <10 seconds) and air-leakage 
checks (pass threshold: loss of <6 mmHg 
over 60 seconds at a stabilised pressure 
of 280 mmHg). Results were documented 
on a monitor testing form (Supplementary 
Information S2). With a conservative 
assumption of a failure rate of 50%, it was 
estimated that a sample size of 385 was 
required, using a 95% confidence interval 
(CI) width of +/–5%.
The mean absolute error (MAE) for 
each monitor was calculated as the 
average (arithmetic mean) of the absolute 
difference — whichever is larger and 
positive of monitor blood pressure minus 
reference blood pressure, and reference 
blood pressure minus monitor blood 
pressure — at each test. The relationship 
between monitor accuracy and make and 
model, length of time in use, frequency 
of recorded uses, monitor purchase price, 
and validation status was assessed using 
linear regression with MAE as the outcome. 
All model assumptions were checked. 
Failure rate by the different predictors was 
assessed using Fisher’s exact test statistic.
RESULTS
Sample
In total, 6891 patients appearing on the 
hypertension register for seven GP 
practices were invited to take part; 1543 
(22%) responses were received. Of these, 
653 (42%) patients owned monitors, of 
whom 526 (81%) expressed an interest in 
having their monitor tested. A total of 410 
(78%) of the 526 monitors were provided for 
testing; 79 (19%) of these proved untestable 
because of the impossibility of separating 
the monitor from the cuff to test each 
component independently — these were, 
typically, wrist monitors. The 331 monitors 
tested comprised more than 50 different 
models, with the majority coming from 
three manufacturers: Boots (n = 62), Lloyds 
(n = 131), and Omron (n = 108). 
Device accuracy
In total, 250 devices (76%, 95% CI = 71 to 
80%) passed on all tests (monitors and cuffs); 
49 (15%, 95% CI = 11 to 18%) monitors failed, 
largely on the accuracy test (n = 46; 14%, 
95% CI = 10 to 18%), and 39 (12%, 95% CI = 8 
How this fits in 
Self-monitoring blood pressure (BP) is 
common, but the accuracy of patients’ own 
monitors is currently unclear. This study 
provides evidence that the accuracy of 
some monitors used at home is similar to 
that of those used in professional settings, 
albeit with more frequent cuff failure. The 
study also found that validated monitors, 
those costing >£10, and those in use for 
≤4 years were more likely to perform 
better. Clinicians can be reassured that 
patients’ own BP monitors are likely to 
be accurate if a validated model that is 
≤4 years old is being used.
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to 15%) overestimated pressure. Table 1 
details the MAE between the reference and 
tested devices. Four monitors had internal 
corrosion or could not hold pressure and, as 
such, could not be subjected to the full range 
of testing once they had definitively failed.
The largest difference from the reference 
monitor was 11.4 mmHg (data not shown). 
In total, 17 (5% (95% CI = 3 to 8%) monitors 
failed by >5 mmHg (data not shown) 
and 23 (7%, 95% CI = 4 to 10%) failed at 
the 150 mmHg level, which is closest 
to the threshold used for diagnosis and 
treatment. The overall MAE (all monitors 
tested) rose at each tested pressure 
interval to 1.5 mmHg (95% CI = 1.3 to 
1.6 mmHg) at 280/300 mmHg (depending 
on the maximum specified pressure for a 
given monitor), compared with 0.6 mmHg 
(95% CI = 0.5 to 0.7 mmHg) at 50 mmHg 
and 1.0 mmHg (95% CI = 0.9 to 1.1 mmHg) 
at 150 mmHg (Table 1). 
Length of time in service
Table 2 details the length of time in service 
of the monitors tested. In total, there was 
no information on years in service for 48 
monitors. Of those monitors on which the 
full range of tests were performed and for 
which owners could provide a reasonable 
estimate regarding the number of years 
in service (n = 279), 188 (67%) had been in 
use for >2 years, and some for substantially 
longer — 61 (22%) monitors had been in use 
for >7 years and one was reported as having 
been in use for >20 years. Overall, the MAE 
tended to increase with length of time in 
service (P<0.001), though sample sizes were 
small in some categories (such as 6–7 years 
and >10 years). The failure rate was 5% 
(8/155) for the first 4 years in service, rising 
to 26% (32/124) for older models.
Previous testing
Only 58 (9%) of the initial 653 responders 
reported having had their device tested 
previously: 22 said their monitors had 
been tested within the previous 2 years, 
25 said they had been tested ≥2 years ago, 
and 11 gave no details about the date of 
previous testing (data not shown). Of the 58 
responders, 40 checked device accuracy by 
comparing results with readings generated 
by an HCP (GP/nurse/pharmacist) and 
five had checked their machine with the 
manufacturer; the remaining 13 provided 
no information. Of 26 previously tested 
monitors tested again by the authors, eight 
failed (31%, 95% CI = 26 to 36%, P = 0.48 for 
difference between previously tested and 
never tested). 
Frequency of use
Table 3 shows the estimates regarding 
how often the devices were used. There 
appeared to be only a limited relationship 
between the frequency of use and the MAE. 
The failure rate for monitors used once a 
month or more was 9% (17/183) compared 
with 22% (28/129) for those used less than 
once a month (P<0.01).
Validation
Of those monitor models for which the 
validation status could be definitively 
Table 1. Mean absolute error between the values reported by the 
reference device and test devices (n = 327) at the pressure intervals 
testeda
Test pressure,  MAE, mmHg Failing  Overestimation  Underestimation  
mmHgb (95% CI) monitors, n (%) by ≥3 mmHg, n by ≥3 mmHg, n
0 0.27 (0.23 to 0.30) 0 (0) 0 0
50  0.59 (0.54 to 0.65) 3 (1) 1 2
100 0.78 (0.70 to 0.86) 6 (2) 4 2
150 0.98 (0.88 to 1.09) 23 (7) 21 2
200  1.14 (1.01 to 1.27) 30 (9) 28 2
250 1.34 (1.18 to 1.49) 41 (13) 35 6
Maximum 1.46 (1.29 to 1.63) 43 (13) 37 6
aFour monitors could not be tested fully but should be counted as failures. bPressure is checked in 50 mmHg 
increments up to either 280 mmHg or 300 mmHg (according to manufacturer’s specification, the highest pressure 
point monitors can be tested at is either 280 mmHg or 300 mmHg) and then down again. The data at each testing 
interval between 0 mmHg and 250 mmHg going up have been combined with that going down. CI = confidence 
interval. MAE = mean absolute error.
Table 2. Mean absolute error compared with reference device, and 
failure rate of tested monitors (n = 327) by length of time in servicea
  
 Monitors, Failing monitors, Cumulative failing MAE, mmHg 
Years in service n n (%)b monitors, n (%)c (95% CI)
0–1 41 0 0 0.63 (0.55 to 0.72)
>1–2 50 5 (10) 5 (5) 0.73 (0.66 to 0.81)
>2–3 36 1 (3) 6 (5) 0.62 (0.53 to 0.71)
>3–4 28 2 (7) 8 (5) 0.80 (0.70 to 0.90)
>4–5 29 6 (21) 14 (8) 1.03 (0.93 to 1.13)
>5–6 20 7 (35) 21 (10) 1.44 (1.32 to 1.56)
>6–7 14 2 (14) 23 (11) 0.88 (0.73 to 1.02)
>7–10 54 15 (28) 38 (14) 1.18 (1.10 to 1.25)
>10 7 2 (29) 40 (14) 1.29 (1.08 to 1.50)
Not stated/monitor owner 48 6 (13) n/a 0.89 (0.81 to 0.97) 
unable to remember
aFour monitors could not be tested fully but should be counted as failures. bPercentage of total monitors per years-
in-service classification. cPercentage of cumulative total of monitors per years-in-service classification and shorter 
lengths of service. MAE = mean absolute error.
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identified (n = 317), 218 (69%) were validated 
and 99 (31%) were not: 209 (96%, 95% CI = 94 
to 98%) of the validated monitors passed all 
the device tests compared with 63 (64%, 
95% CI = 58 to 69%) of the unvalidated 
monitors (P<0.001 for the comparison).
Cuff functionality
Table 4 shows that 287 (78%, 95% CI = 74 
to 82%) of the cuffs were medium-sized 
(22–32 cm) and 57 (15%) large; it should be 
noted that some devices had multiple cuffs. 
Cuff air leakage resulted in failure for 44 
(12%) of 369 cuffs (95% CI = 8 to 15%). The 
failure rate was higher (P = 0.002) in large 
cuffs (26%, 95% CI = 22 to 31%) than in those 
that were medium sized (10%, 95% CI = 7 to 
13%). Other cuff-size categories had too few 
cases to be evaluated. Failure of the cuff 
air-leakage tests contributed to the overall 
failure rate as described above.
Purchase price
The reported original purchase price of 
devices varied from £5 to just over £100, 
with one outlier costing £240 and another 
acquired for free. Table 5 shows the 
relationship between purchase price and 
failure rate for those devices with data for 
both variables (n = 240). The vast majority 
(188/240, 78%) cost ≤£30, with the modal 
decile being £11–20 (n = 100). Monitor failure 
rate was highest for the cheapest machines 
(14 [34%] of 41 devices costing £1–10 
failed); it improved as devices became more 
expensive, and (3 [6%] of the 52 devices 
costing >£31 failed [P<0.001]). However, 
including cuff failure rate resulted in no 
difference overall in failure by device cost. 
Regression analysis
A regression model identified that length 
of time in service (8% increase in MAE 
for each additional year of service) and 
validation status (validated models having 
a 23% decrease in MAE compared with 
unvalidated monitors) were statistically 
significant predictors of MAE, but estimated 
frequency of use, previous testing, and cost 
of device were not (Table 6). 
Due to the sheer diversity of models 
encountered, the intention to conduct an 
analysis of the performance of different 
makes and models proved impossible. In the 
regression model, any discernible difference 
in performance characteristics was explained 
by the validation status of the device type.
DISCUSSION
Summary
This first study (to the authors’ knowledge)
of accuracy of patients’ own monitors in the 
Table 3. Mean absolute error compared with reference device and 
failure rate of monitors (n = 327) by frequency of usea
Frequency of use Monitors, n Failing monitors, n (%)b MAE, mmHg (95% CI)
>10 times a month 27 3 (11) 0.89 (0.84 to 0.94)
6–10 times a month 41 2 (5) 0.74 (0.69 to 0.78)
1–5 times a month 115 12 (10) 0.86 (0.84 to 0.89)
6–11 times a year 57 13 (23) 1.08 (1.04 to 1.11)
1–5 times a year 44 10 (23) 0.96 (0.92 to 1.00)
Less frequently 28 5 (18) 0.94 (0.88 to 0.99)
Not stated 15 1 (7) 0.67 (0.60 to 0.74)
aFour monitors could not be tested fully but should be counted as failures. bPercentage of total monitors per 
frequency-of-use classification. CI = confidence interval. MAE = mean absolute error.
Table 4. Failure rates of cuffs by cuff size
Cuff size (cm) Cuffs tested, n a Failures, n (%)b 95% CI
Small (17–22) 2 0 (0) n/a
Medium (22–32) 287 28 (10) 7 to 13
Large (32–42) 57 15 (26) 22 to 31
Extra large (42–48) 1 0 (0) n/a
Universal — medium–large (22–42) 19 0 (0) n/a
Other/unclear 3 1 (33) n/a
aSome monitors came with multiple cuffs. bPercentage of total cuffs per size classification.
Table 5. Failure rate by approximate purchase price of monitor
   All 
  Monitor monitor 
Purchase  pass, pass, Monitor All fail,  
price, £ Pass cuff fail, n n (%)a fail, n (%a)  n (%) Total, n
0–10 27 0 27 (66) 14 (34) 14 (34) 41
11–20 77 10 87 (87) 13 (13) 23 (23) 100
21–30 40 3 43 (91) 4 (9) 7 (15) 47
>31 41 8 49 (94) 3 (6) 11 (21) 52
Total 185 21 206 34 55 240
Full breakdown for monitors costing >£30
31–40 13 1 14 1 2 15
41–50 8 3 11 1 4 12
51–60 8 2 10 0 2 10
61–70 2 0 2 0 0 2
71–80 3 2 5 1 3 6
81–90 1 0 1 0 0 1
91–100 5 0 5 0 0 5
>100 1 0 1 0 0 1
aPercentage of total monitors by purchase-price classification.
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UK found that approximately three-quarters 
of monitors and/or the matching cuff passed 
a standard calibration test. Inaccurate 
monitors generally overestimated BP, and 
large cuffs were more than twice as likely 
to fail as those that were medium sized. 
Validated monitors, those costing >£10, 
and those that were ≤4 years old were most 
likely to be accurate.
Strengths and limitations 
This work provides robust data to answer 
a question often raised by clinicians6 —
namely, ‘how accurate is patients’ own 
BP monitoring equipment?’ — and one 
that is important in terms of planning the 
implementation of BP self-monitoring on 
a wider scale. Assessing a large number of 
monitors across several practices covering 
different sociodemographic strata provides 
reassurance that these results are likely 
to be generalisable, more so than previous 
smaller studies, despite a response rate of 
<25%. Fewer than one in 10 monitors had 
had any kind of previous evaluation, so such 
information is important.
It should be noted, however, that it was only 
possible to assess the accuracy of monitors 
that participants brought to be tested, which 
may represent a biased sample. A number 
of monitor types — primarily, wrist monitors 
for which there is no way of separating 
the cuff from the monitor — could not 
be tested using the researchers’ standard 
calibration equipment (Omron PA350); 
however, current guidance recommends 
the use of upper-arm devices, which the 
authors were, in general, able to test.
Data on frequency of use, length 
of time in service, purchase price, and 
previous testing were reliant on participant 
recall and, as such, may be subject to 
confounding, for example, devices in which 
users have more confidence (because of 
their apparent accuracy) may be used more 
frequently. However, any kind of evaluation 
of potential factors explaining variations 
in monitor performance is, to the authors’ 
knowledge, unique to this study.
Comparison with existing literature
At 42%, ownership of home BP monitors 
in the study presented here was slightly 
higher than in previous published surveys 
of patients with hypertension in the UK,17 
but is in keeping with GPs' estimates of 
patient self-monitoring.6 This is perhaps 
unsurprising, given the likelihood of 
preferential responses from monitor 
owners who wanted their equipment tested, 
although the authors emphasised also 
being interested in receiving null responses 
and included a self-addressed envelope to 
encourage all those contacted to respond.
Previous work from outside of the UK has 
generally found much worse performance 
than found in the study presented here: 
a Canadian study18 conducted between 
2011 and 2014 found that around a third 
of patients’ monitors showed a difference 
of >5 mmHg (systolic and/or diastolic) 
compared with a mercury measurement. 
No statistically significant difference was 
found between monitors that were accurate 
versus those that were not when grouped 
according to patient characteristics, cuff 
size, or the brand of the home monitor 
in the Canadian study.18 Even greater 
inaccuracy was identified by a different 
Canadian group, with 69% of devices 
showing differences of ≥5 mmHg and no 
improvement in performance for validated 
machines.19 However, a Korean study20 
using the same methodology found monitor 
failure rates of 15% — similar to those in the 
study presented here — and that inaccuracy 
was more common in unvalidated devices 
(19%, 25/130) than those that were validated 
(7%, 6/82). 
A Turkish study,21 again using similar 
methods (although with 4 mmHg as the 
threshold for failure), identified inaccuracy 
rates of 59%, inaccuracy rates of 67% in 119 
upper-arm devices. The same sample of 
Table 6. Regression model — mean absolute errora
 Estimate 95% CI P-value
Intercept 0.62 0.37 to 1.04 0.051
Length of time in service 
Years in service (each additional year) 1.08 1.04 to 1.12 <0.001
Frequency of use   
 >10 times per month 0.94 0.66 to 1.38 0.76
 6–10 times per month 0.82 0.61 to 1.12 0.19
 1–5 times per month 1 reference 
 6–11 times per year 0.90 0.68 to 1.20 0.47
 1–5 times per year 0.94 0.66 to 1.36 0.74
 Less frequently 0.89 0.61 to 1.32 0.53
 Not known 0.80 0.38 to 2.07 0.61
Cost of device   
 Cost (every £1 increase) 1.00 0.99 to 1.01 0.75
Tested (reference: no)   
 Yes 1.21 0.80 to 1.91 0.38
 Not known 1.10 0.87 to 1.41 0.44
Make (reference: Boots)   
 Lloyds 1.31 0.90 to 1.90 0.13
 Omron 1.01 0.75 to 1.37 0.94
 Other 1.23 0.80 to 1.92 0.34
Validation status (reference: not validated/not applicable)
 Validated  0.77 0.59 to 1.02 0.044
aThe proportion in MAE change is the unit of predictor unless otherwise stated. MAE = mean absolute error.
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monitors showed accuracy was statistically 
significantly greater in validated devices 
(n = 22) compared with unvalidated devices 
(n = 52) (68% versus 15%, P<0.01).22 
Conversely, an earlier Canadian study23 
found no difference in monitor performance 
dependent on validation status but, again, 
included very few monitors (n = 26) that 
had been validated. The research presented 
here confirms the importance of using 
validated devices, which is generally called 
for in guidelines.9
Although it is a concern that several wrist 
monitors were not assessable and almost a 
quarter of the equipment (including cuffs) 
failed, the overall monitor failure rate of 
15% is similar to that previously identified 
in devices used in general practice (13%)10 
and pharmacies (14%).11 In those settings, 
devices were used more frequently but for 
shorter periods. Given that the authors 
of the study presented here employed 
quite stringent criteria — with a difference 
of 3 mmHg throughout the range being 
enough to constitute failure — this suggests 
the majority of home BP monitors can 
be considered reliable enough for use in 
primary care, especially those that are 
newer and validated. 
Implications for practice
An accurate BP monitor is fundamental 
to the diagnosis and management of 
hypertension. Self-monitoring BP devices 
are currently not prescribed on the NHS 
and, to be able to recommend home 
monitoring of BP more widely, there needs 
to be confidence in the devices accessible 
to patients or an ability to provide clear 
guidance on which models to trust, and 
how long for. Monitor manufacturers 
typically recommend annual calibration 
after 2 years’ service. The fact that a small 
proportion of home monitors in use appear 
to be very inaccurate does suggest the need 
for regular performance checks, although 
a more pragmatic approach might be to 
restrict this to unvalidated monitors or 
validated models that are >4 years old. 
This study suggests that validation status 
is a reasonable indicator of both short- and 
longer-term performance; HCPs should 
be encouraged to provide patients with 
clear advice on this. Given the issues with 
cuff failure noted in this study, it might 
be beneficial for manufacturers to develop 
quality-control algorithms that alert users 
when cuffs are not performing properly.
Monitors were more likely to fail the 
accuracy test because of overestimating 
BP rather than underestimating it; this 
suggests that underdiagnosis/treatment 
is less likely than overdiagnosis, which is 
reassuring.
This study suggests that the majority of 
monitors in current use by patients in UK 
primary care are likely to be accurate, and 
GPs should recommend that patients who 
are considering self-monitoring consult 
online lists of validated monitors (for 
example, https://bihsoc.org/bp-monitors/), 
replace monitors every 4 to 5 years, and 
avoid wrist models. Practices using such 
a policy could be confident that managing 
hypertension with such equipment is likely 
to be appropriate; other work by the authors 
suggests this will lead to better BP control.5
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